Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Neurol. 2013 Aug;74(2):297-300. doi: 10.1002/ana.23899.

Inhibiting glycogen synthesis prevents Lafora disease in a mouse model.

Author information

1
Indiana University School of Medicine-Muncie, Ball State University, Muncie, IN.

Abstract

Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.

PMID:
23913475
PMCID:
PMC3823666
DOI:
10.1002/ana.23899
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center